Director Kevin Bitterman filed a Form 4 with the SEC on September 3, 2026, reporting the sale of common stock of Disc Medicine, Inc. (NASDAQ:IRON) across multiple indirectly held fund accounts on September 1, 2, and 3, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Rule 10b5-1 plan: All sales were made pursuant to a trading plan adopted on July 30, 2026, according to the filing.
  • September 1 sales: A total of 129 shares were sold across three fund accounts at $79.95 per share.
  • September 2 sales: A total of 49,164 shares were sold across three fund accounts at weighted average prices of $80.17 and $80.98, with individual transaction price ranges disclosed in footnotes.
  • September 3 sales: A total of 5,203 shares were sold across three fund accounts at a weighted average price of $79.98, with transactions ranging from $79.95 to $80.28.
  • Indirect ownership: All shares are held indirectly through Atlas Venture Opportunity Fund I, Atlas Venture Opportunity Fund II, and Atlas Venture Fund XII; the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
  • Post-transaction holdings: Following all reported transactions, the three fund accounts held 319,778, 312,989, and 13,445 shares, respectively, according to the filing.

Kevin Bitterman's Multi-Day Share Sales in Disc Medicine Across Three Atlas Funds

According to the Form 4 filed September 3, 2026, Kevin Bitterman, a director at Disc Medicine, Inc. (NASDAQ:IRON), reported twelve separate sale transactions in common stock over three consecutive trading days. All sales carried transaction code "S" and were executed under a Rule 10b5-1 trading plan that the filing states was adopted on July 30, 2026. The shares were sold exclusively from accounts held indirectly through three Atlas Venture entities: Atlas Venture Opportunity Fund I, L.P., Atlas Venture Opportunity Fund II, L.P., and Atlas Venture Fund XII, L.P.

On September 1, 2026, the filing reported sales of 70, 58, and 1 shares from the three respective funds, each at $79.95 per share. On September 2, 2026, larger blocks were transacted: 26,542 and 10 shares from Opportunity Fund I, 22,090 and 9 shares from Opportunity Fund II, and 511 and 2 shares from Atlas Fund XII. The September 2 prices were reported as weighted averages of $80.17 and $80.98, with the filing noting that the $80.17 transactions ranged from $79.95 to $80.9421 and the $80.98 transactions ranged from $80.9677 to $81.0079. On September 3, sales of 2,810, 2,339, and 54 shares were recorded at a weighted average of $79.98, with prices ranging from $79.95 to $80.28.

The filing notes that Bitterman is a member of the general partner LLCs for each fund but "disclaims beneficial ownership of such securities," except to the extent of any pecuniary interest. The reporting person undertook, per the footnotes, to provide full per-price transaction detail to the issuer, any security holder, or SEC staff upon request.

What Was Disclosed

Director Kevin Bitterman reported the indirect sale of Disc Medicine common stock across three Atlas Venture funds over September 1-3, 2026, all pursuant to a Rule 10b5-1 plan adopted July 30, 2026, at prices ranging from $79.95 to $81.0079 per share.